China Universal CSI Health Care ETF(159929) Drops 3.47% Intraday,Short-Term Market Under Pressure

NewTimeSpace News: As of 13:54 on March 23, 2026, the CSI Medical Health Index (000933) dropped 3.48%. Among its constituent stocks, Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. led the decline with an 8.77% drop, Baiyunshan Pharmaceutical Holdings Co., Ltd. fell 7.84%, BGI Genomics Co., Ltd. slid 7.59%, Lepu Medical Technology (Beijing) Co., Ltd. dropped 6.98%, and Shandong Buchang Pharmaceutical Co., Ltd. fell 6.85%. TheChina Universal CSI Health Care ETF(159929) declined 3.47% to a latest price of RMB 1.25. Over a longer time frame, as of March 20, 2026, theChina Universal CSI Health Care ETFhad a cumulative increase of 1.97% in the past year. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

In terms of liquidity, theChina Universal CSI Health Care ETFrecorded an intraday turnover rate of 4.15% with a trading volume of RMB 97.0306 million. Looking back, as of March 20, the average daily trading volume of theChina Universal CSI Health Care ETFstood at RMB 76.7818 million in the past year.

In terms of scale, the latest scale of theChina Universal CSI Health Care ETFreached RMB 2.384 billion. (Data source: Wind)

In terms of capital inflows, theChina Universal CSI Health Care ETFhas seen consecutive net capital inflows over the past three days, with a maximum single-day net inflow of RMB 5.9655 million, raking in a total of RMB 11.8857 million and an average daily net inflow of RMB 3.9619 million. (Data source: Wind)

Data showed that leveraged funds have been continuously building positions in the ETF. The latest margin purchase volume of theChina Universal CSI Health Care ETFhit RMB 4.5670 million, with the latest margin balance standing at RMB 71.5253 million. (Data source: Wind)

As of March 20, the net asset value (NAV) of theChina Universal CSI Health Care ETFhad risen 0.47% in the past year. In terms of earnings capacity, as of March 20, 2026, since its inception, the ETF has achieved a maximum monthly return of 23.11%, a longest consecutive monthly gain streak of 8 months with a cumulative increase of 63.16% during the streak, a ratio of up months to down months of 79:71, and an average monthly return of 5.34% in positive months. The historical probability of making a profit with a 3-year holding period is 61.47%. As of March 20, 2026, theChina Universal CSI Health Care ETFhad an annualized excess return of 1.20% over the benchmark in the past two years.

In terms of drawdown, as of March 20, 2026, theChina Universal CSI Health Care ETFhad a relative drawdown of 0.05% against the benchmark since the start of the year.

In terms of fees, theChina Universal CSI Health Care ETFhas a management fee rate of 0.50% and a custodian fee rate of 0.10%.

In terms of tracking accuracy, as of March 20, 2026, theChina Universal CSI Health Care ETFhad a tracking error of 0.008% in the past month.

Notably, the CSI Medical Health Index tracked by the fund is at a historically low valuation level, with the latest price-to-book ratio (PB) standing at 3.04 times, lower than that in more than 89.54% of the time since the index's inception, representing a prominent valuation cost performance.

TheChina Universal CSI Health Care ETFclosely tracks the CSI Medical Health Index. To reflect the overall performance of securities of companies in different industries within the CSI 800 Index sample and provide an analytical tool for investors, the CSI 800 Index sample is divided into 11 first-level industries and 35 second-level industries according to the CSI Industry Classification. Indices are then compiled with all securities in each first-level and second-level industry as samples, forming the CSI 800 Industry Indices series.

Data showed that as of February 27, 2026, the top 10 weight stocks of the CSI Medical Health Index (000933) were WuXi AppTec Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Mindray Medical International Limited, United Imaging Healthcare Co., Ltd., Yunnan Baiyao Group Co., Ltd., Aier Eye Hospital Group Co., Ltd., Zhangzhou Pientzehuang Pharmaceutical Co., Ltd., Zhejiang NHU Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd. and Fosun Pharmaceutical (Group) Co., Ltd. in sequence, with the combined weight of the top 10 stocks accounting for 43.48%. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

SWSC stated that cost-effective domestic automated laboratory lines and reagents with stable test results are entering a crucial window period for hospital replacement. This will also drive the rapid improvement of the concentration of the in-vitro diagnosis (IVD) industry, leading to a red-sea competition in the stock market. Deprived of the protection from methodological premium, some foreign brands and high-premium domestic products will face pressure. Homogeneous competition in conventional testing fields such as biochemistry and general immunology will shift to price wars, and the living space for small and medium-sized enterprises will be greatly squeezed.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.